# Verastem, Inc.: financial statements, quarterly

VSTM · Nasdaq · CIK 1526119 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vstm.md) · [Financials](/companies/vstm/financials.md) · [Filings](/companies/vstm/filings.md) · [Insiders](/companies/vstm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vstm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [10.0](/filings/0001558370-24-011599.md) | [0.0 d](/filings/0001558370-24-014640.md) | [0.0 d](/filings/0001558370-25-003372.md) | not reported | [2.1](/filings/0001104659-26-092007.md) | [11.2](/filings/0001104659-25-106279.md) | [17.5 d](/filings/0001104659-26-023444.md) | [18.7](/filings/0001104659-26-057114.md) | [40.1](/filings/0001104659-26-092007.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [13.9](/filings/0001558370-24-014640.md) | [22.5 d](/filings/0001104659-26-023444.md) | [17.7](/filings/0001558370-25-007570.md) | [18.1](/filings/0001558370-25-010757.md) | [24.8](/filings/0001104659-25-106279.md) | [20.8 d](/filings/0001104659-26-023444.md) | [29.2](/filings/0001104659-26-057114.md) | [24.8](/filings/0001104659-26-092007.md) | [29.0](/filings/0001104659-25-106279.md) | [31.7 d](/filings/0001104659-26-023444.md) | [38.2](/filings/0001104659-26-057114.md) | [41.3](/filings/0001104659-26-092007.md) |
| Selling, general and administrative | $m | [7.4](/filings/0001558370-24-014640.md) | [8.6 d](/filings/0001104659-26-023444.md) | [10.4](/filings/0001558370-25-007570.md) | [10.2](/filings/0001558370-25-010757.md) | [12.3](/filings/0001104659-25-106279.md) | [10.8 d](/filings/0001104659-26-023444.md) | [15.0](/filings/0001104659-26-057114.md) | [20.7](/filings/0001104659-26-092007.md) | [21.0](/filings/0001104659-25-106279.md) | [24.4 d](/filings/0001104659-26-023444.md) | [22.3](/filings/0001104659-26-057114.md) | [27.4](/filings/0001104659-26-092007.md) |
| Operating income | $m | [(21.3)](/filings/0001558370-24-014640.md) | [(31.1) d](/filings/0001104659-26-023444.md) | [(28.1)](/filings/0001558370-25-007570.md) | [(18.3)](/filings/0001558370-25-010757.md) | [(37.0)](/filings/0001104659-25-106279.md) | [(31.6) d](/filings/0001104659-26-023444.md) | [(44.2)](/filings/0001104659-26-057114.md) | [(43.8)](/filings/0001104659-26-092007.md) | [(40.7)](/filings/0001104659-25-106279.md) | [(41.5) d](/filings/0001104659-26-023444.md) | [(44.9)](/filings/0001104659-26-057114.md) | [(32.7)](/filings/0001104659-26-092007.md) |
| Interest expense | $m | [1.1](/filings/0001558370-24-014640.md) | [1.1 d](/filings/0001104659-26-023444.md) | [1.1](/filings/0001558370-25-007570.md) | [1.1](/filings/0001558370-25-010757.md) | [1.1](/filings/0001104659-25-106279.md) | [1.1 d](/filings/0001104659-26-023444.md) | [0.2](/filings/0001104659-26-057114.md) | [0.2](/filings/0001104659-26-092007.md) | [0.3](/filings/0001104659-25-106279.md) | [0.4 d](/filings/0001104659-26-023444.md) | [0.4](/filings/0001104659-26-057114.md) | [0.4](/filings/0001104659-26-092007.md) |
| Income tax | $m | [0.0](/filings/0001558370-24-014640.md) | not reported | [0.0](/filings/0001558370-25-007570.md) | [0.0](/filings/0001558370-24-011599.md) | [0.0](/filings/0001558370-24-014640.md) | [0.2 d](/filings/0001104659-26-023444.md) | [0.0](/filings/0001104659-26-057114.md) | [0.0 d](/filings/0001558370-25-010757.md) | [0.0 d](/filings/0001104659-25-106279.md) | not reported | [0.0](/filings/0001104659-26-057114.md) | [0.8](/filings/0001104659-26-092007.md) |
| Net income | $m | [(20.0)](/filings/0001558370-24-014640.md) | [(27.4) d](/filings/0001104659-26-023444.md) | [(33.9)](/filings/0001104659-25-106279.md) | [(8.3)](/filings/0001104659-25-106279.md) | [(24.0)](/filings/0001104659-25-106279.md) | [(64.6) d](/filings/0001104659-26-023444.md) | [(52.1)](/filings/0001104659-26-092007.md) | [(25.9)](/filings/0001104659-26-092007.md) | [(98.5)](/filings/0001104659-25-106279.md) | [(32.9) d](/filings/0001104659-26-023444.md) | [(36.6)](/filings/0001104659-26-092007.md) | [(34.7)](/filings/0001104659-26-092007.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0001558370-24-014640.md) | not reported | [(1.26)](/filings/0001558370-25-007570.md) | [(0.31)](/filings/0001558370-25-010757.md) | [(0.60)](/filings/0001104659-25-106279.md) | not reported | [(0.96)](/filings/0001104659-26-057114.md) | [(0.62)](/filings/0001104659-26-092007.md) | [(1.35)](/filings/0001104659-25-106279.md) | not reported | [(0.46)](/filings/0001104659-26-057114.md) | [(0.35)](/filings/0001104659-26-092007.md) |
| Basic EPS | $ per share | [(0.75)](/filings/0001558370-24-014640.md) | not reported | [(1.26)](/filings/0001558370-25-007570.md) | [(0.31)](/filings/0001558370-25-010757.md) | [(0.60)](/filings/0001104659-25-106279.md) | not reported | [(0.96)](/filings/0001104659-26-057114.md) | [(0.39)](/filings/0001104659-26-092007.md) | [(1.35)](/filings/0001104659-25-106279.md) | not reported | [(0.37)](/filings/0001104659-26-057114.md) | [(0.35)](/filings/0001104659-26-092007.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [95.0](/filings/0001558370-23-018281.md) | [77.9](/filings/0001558370-25-003372.md) | [81.3](/filings/0001558370-24-007607.md) | [83.4](/filings/0001558370-24-011599.md) | [113](/filings/0001558370-24-014640.md) | [88.8](/filings/0001104659-26-023444.md) | [118](/filings/0001558370-25-007570.md) | [164](/filings/0001558370-25-010757.md) | [138](/filings/0001104659-25-106279.md) | [205](/filings/0001104659-26-092007.md) | [166](/filings/0001104659-26-057114.md) | [136](/filings/0001104659-26-092007.md) |
| Current assets | $m | [174](/filings/0001558370-23-018281.md) | [144](/filings/0001558370-25-003372.md) | [118](/filings/0001558370-24-007607.md) | [99.6](/filings/0001558370-24-011599.md) | [121](/filings/0001558370-24-014640.md) | [95.0](/filings/0001104659-26-023444.md) | [125](/filings/0001558370-25-007570.md) | [174](/filings/0001558370-25-010757.md) | [154](/filings/0001104659-25-106279.md) | [223](/filings/0001104659-26-092007.md) | [203](/filings/0001104659-26-057114.md) | [176](/filings/0001104659-26-092007.md) |
| Total assets | $m | [176](/filings/0001558370-23-018281.md) | [150](/filings/0001558370-25-003372.md) | [124](/filings/0001558370-24-007607.md) | [106](/filings/0001558370-24-011599.md) | [126](/filings/0001558370-24-014640.md) | [102](/filings/0001104659-26-023444.md) | [132](/filings/0001558370-25-007570.md) | [196](/filings/0001558370-25-010757.md) | [177](/filings/0001104659-25-106279.md) | [246](/filings/0001104659-26-092007.md) | [228](/filings/0001104659-26-057114.md) | [207](/filings/0001104659-26-092007.md) |
| Current liabilities | $m | [23.8](/filings/0001558370-23-018281.md) | [26.4](/filings/0001558370-25-003372.md) | [26.7](/filings/0001558370-24-007607.md) | [30.3](/filings/0001558370-24-011599.md) | [37.4](/filings/0001558370-24-014640.md) | [31.0](/filings/0001104659-26-023444.md) | [35.6](/filings/0001558370-25-007570.md) | [50.4](/filings/0001558370-25-010757.md) | [59.7](/filings/0001104659-25-106279.md) | [72.3](/filings/0001104659-26-092007.md) | [66.8](/filings/0001104659-26-057114.md) | [78.1](/filings/0001104659-26-092007.md) |
| Total liabilities | $m | [71.8](/filings/0001558370-23-018281.md) | [71.2](/filings/0001558370-25-003372.md) | [77.3](/filings/0001558370-24-007607.md) | [65.7](/filings/0001558370-24-011599.md) | [94.2](/filings/0001558370-24-014640.md) | [130](/filings/0001104659-26-023444.md) | [164](/filings/0001558370-25-007570.md) | [160](/filings/0001558370-25-010757.md) | [192](/filings/0001104659-25-106279.md) | [189](/filings/0001104659-26-092007.md) | [146](/filings/0001104659-26-057114.md) | [157](/filings/0001104659-26-092007.md) |
| Long-term debt | $m | [39.9](/filings/0001558370-23-018281.md) | [40.1](/filings/0001558370-25-003372.md) | [40.1](/filings/0001558370-24-007607.md) | [40.3](/filings/0001558370-24-011599.md) | [40.5](/filings/0001558370-24-014640.md) | [40.7](/filings/0001104659-26-023444.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [83.2](/filings/0001558370-24-014640.md) | [57.4](/filings/0001104659-26-023444.md) | [25.1](/filings/0001104659-25-106279.md) | [18.9](/filings/0001104659-25-106279.md) | [11.1](/filings/0001104659-25-106279.md) | [(28.9)](/filings/0001104659-26-092007.md) | [(32.4)](/filings/0001104659-26-092007.md) | [36.1](/filings/0001104659-26-092007.md) | [(15.5)](/filings/0001104659-25-106279.md) | [57.2](/filings/0001104659-26-092007.md) | [81.8](/filings/0001104659-26-092007.md) | [50.0](/filings/0001104659-26-092007.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.6) d](/filings/0001558370-24-014640.md) | [(29.7) d](/filings/0001104659-26-023444.md) | [(28.3)](/filings/0001558370-25-007570.md) | [(27.6) d](/filings/0001558370-25-010757.md) | [(23.8) d](/filings/0001104659-25-106279.md) | [(25.1) d](/filings/0001104659-26-023444.md) | [(38.7)](/filings/0001104659-26-057114.md) | [(32.7) d](/filings/0001104659-26-092007.md) | [(36.2) d](/filings/0001104659-25-106279.md) | [(30.0) d](/filings/0001104659-26-023444.md) | [(52.1)](/filings/0001104659-26-057114.md) | [(43.9) d](/filings/0001104659-26-092007.md) |
| Capital expenditure | $m | not reported | not reported | [0.0](/filings/0001558370-25-007570.md) | [0.0 d](/filings/0001558370-25-010757.md) | [0.0 d](/filings/0001104659-25-106279.md) | [0.0 d](/filings/0001104659-26-023444.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q3 FY2023 (2023-09-30) | period not labelled (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [186](/filings/0001558370-22-012638.md) | [197](/filings/0001558370-22-016278.md) | [201](/filings/0001558370-24-007607.md) | [26.8](/filings/0001558370-24-014640.md) | [26.8](/filings/0001558370-25-007570.md) | [26.9](/filings/0001558370-25-010757.md) | [40.3](/filings/0001104659-25-106279.md) | [54.2](/filings/0001104659-26-057114.md) | [74.0](/filings/0001104659-26-092007.md) | [73.2](/filings/0001104659-25-106279.md) | [99.1](/filings/0001104659-26-057114.md) | [100](/filings/0001104659-26-092007.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 90,563,441 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092007.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.